Abstract
The impact of the CD34+ cell dose on chronic graft-versus-host disease (cGVHD) and the clinical outcome was analyzed in 41 consecutive adult patients submitted to allogeneic peripheral blood stem cell transplantation from HLA-identical siblings. The patients were classified into 'low' or 'high' CD34+ cell dose groups based on whether they received less or more than a median CD34+ cell dose of 10.5 x 10(6)/kg, respectively. There was a significant difference in the incidence of extensive cGVHD (low vs high group, 25.0 vs 66.7%, P=0.021) and relapse (47.6 vs 20.0%, P=0.049) between the two groups. With a median follow-up of 335 days, the 3-year survival estimate for the whole population was 47.9%, while that for the low and high groups was 29.9 and 67.8%, respectively (P=0.0434). An inverse relation was noted between the relapse rate and the incidence of extensive cGVHD (P=0.043). It would appear reasonable that the optimal dose of CD34+ cells should be determined based on the disease status or aggressiveness of the malignant cells in each patient. Yet, in the case of patients with a high risk of relapse, transplantation with a CD34+ cell dose of >10.5 x 10(6)/kg would seem to be acceptable to minimize the risk of relapse.
References
Apr 17, 1975·The New England Journal of Medicine·E ThomasC D Buckner
Feb 26, 2000·British Journal of Haematology·E BahçeciA J Barrett
Oct 6, 2000·Bone Marrow Transplantation·S SinghalJ Mehta
Apr 25, 2001·Bone Marrow Transplantation·R Morariu-ZamfirE Gluckman
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C CutlerJ H Antin
Sep 6, 2001·Blood·D PrzepiorkaR Champlin
Sep 6, 2001·Blood·M RembergerV Runde
Sep 13, 2001·British Journal of Haematology·S BrunetUNKNOWN Spanish Group of Allogenic-PBT, Spain
Oct 6, 2001·Blood·A Urbano-IspizuaE Montserrat
Nov 24, 2001·Blood·J M ZauchaB Torok-Storb
Nov 28, 2001·British Journal of Haematology·R NakamuraA J Barrett
Jan 30, 2002·Cancer·Sang-Kyun SohnKyu-Bo Lee
Apr 4, 2002·Blood·Henrique BittencourtEliane Gluckman
Jul 20, 2002·Bone Marrow Transplantation·S K SohnK B Lee
Citations
Feb 24, 2010·Annals of Hematology·Byung Woog KangSang Kyun Sohn
Feb 26, 2005·Experimental Hematology·Thai M CaoRobert Lowsky
Jun 29, 2005·Acta Haematologica·Dong Hwan KimKyu Bo Lee
Dec 7, 2011·Acta Haematologica·Soo Jung LeeSang-Kyun Sohn
Sep 1, 2005·Blood·Bipin N SavaniA John Barrett
Feb 14, 2008·PloS One·Mark D UngrinPeter W Zandstra
Jul 9, 2004·International Journal of Hematology·Sang Kyun SohnKyu Bo Lee
Sep 9, 2005·European Journal of Haematology·Dong Hwan KimIm Hee Shin
May 7, 2004·European Journal of Haematology·Sang Kyun SohnKyu Bo Lee
Jan 21, 2006·Journal of Clinical Apheresis·Sang Kyun SohnDong Hwan Kim
May 12, 2007·Clinical and Experimental Immunology·J ClausenD Nachbaur
Jun 6, 2008·American Journal of Hematology·Yee Soo ChaeGoon Jae Cho
Nov 23, 2013·Transfusion·Sang Kyun Sohn, Joon Ho Moon
Feb 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anurag K SinghA John Barrett
Jan 18, 2006·Experimental Hematology·Nathalie DhédinJean Roy
Jul 6, 2011·Biotechnology Advances·Carlos A V RodriguesJoaquim M S Cabral
Jun 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dong Hwan KimKyu Bo Lee
Dec 13, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aldemar MonteroA John Barrett
Sep 30, 2014·Bone Marrow Transplantation·J W LeeH-K Kim
May 11, 2004·Bone Marrow Transplantation·S K SohnK B Lee
Apr 18, 2020·American Journal of Hematology·Enrico MaffiniMohamad Mohty
Feb 12, 2020·Bone Marrow Transplantation·Yasuhisa YokoyamaShigeru Chiba
Sep 12, 2018·Chinese Medical Journal·Le-Qing CaoYing-Jun Chang
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Caroline PabstUwe Platzbecker